{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"2.1","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"TTR is defined as the time from the date of first dose of study treatment to first documented response (PR or nCR or CR) per modified EBMT criteria as assessed by investigator","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.","reportingStatus":"POSTED","timeFrame":"duration of study up to approx. 4 years","title":"Time to Response (TTR) Per Investigator","type":"SECONDARY","unitOfMeasure":"months"}